Allo-CAR-T: A Glimmer of Hope for Relapsed Plasma Cell Leukemia
Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma. There are two types:
Primary PCL (pPCL): diagnosed at first presentation.
Secondary PCL (sPCL): develops when multiple myeloma transforms or relapses with PCL characteristics.
Each year, about 200 people are diagnosed with PCL in the United States. Despite major advances in myeloma care, PCL outcomes remain poor. The median overall survival (OS) for pPCL is approximately three years, although patients who undergo tandem (back-to-back) autologous stem cell transplants may live up to six years (Journal Blood).
For secondary PCL, outcomes are worse. The median survival is about three months with one transplant and 16 months with tandem transplants (auto/allo or allo/allo). Relapsed cases typically have very limited options.
A slow treatment progress demands more research efforts
Although new myeloma therapies, like bispecific antibodies, CAR-T cells, and targeted drugs, have extended survival for many patients, people with PCL have not benefited in the same way.
This is largely because PCL patients are often excluded from clinical trials. Without study data, oncologists lack evidence on how new treatments perform in this population. As a result, PCL patients rarely gain access to these novel options outside of compassionate use or investigator-initiated studies.
People with PCL deserve inclusion in future trials so that research findings can guide their care and improve access to modern treatments.
What is Allo-CAR-T therapy?
Allogeneic CAR-T (allo-CAR-T) therapy uses donor T cells rather than a patient’s own cells. This makes it an “off-the-shelf” option, meaning treatment can start almost immediately, which is critical for ultra-high-risk diseases like PCL, where rapid progression is common.
However, allo-CAR-T therapy has a challenge: the patient’s immune system can attack and destroy the donor cells, limiting their persistence and benefit.
To address this, Carsgen Therapeutics developed CT0596, an allo-CAR-T targeting BCMA (B-cell maturation antigen). This version is “armored” with an additional receptor that recognizes NKG2A, a surface protein on natural killer (NK) cells. This feature helps the CAR-T cells evade destruction by the patient’s immune system, potentially extending their activity.
To learn more about CAR-T therapy visit our free educational guide
Encouraging early results in plasma cell leukemia
A press release from Carsgen Therapeutics shared early findings from the first two PCL patients treated with CT0596. Both had heavily pretreated disease, including prior exposure to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies.
Reported side effects were consistent with other CAR-T therapies: cytokine release syndrome, low blood cell counts and lung infection. However people who presented these side effects were able to recover fully after treatment with tocilizumab and supportive care.
Participants achieved stringent complete response (sCR) and were MRD-negative at Week 4.
These are remarkable results for PCL, where complete responses are rarely seen. Time will tell how durable these outcomes are and whether side effects like graft-versus-host disease (GvHD) emerge later.
What comes next for CT0596 and other PCL therapies
Carsgen, headquartered in China, also operates an FDA-approved manufacturing facility in Durham, North Carolina. The company plans to file an Investigational New Drug (IND) application with the U.S. FDA soon to begin domestic clinical trials of CT0596.
Carsgen’s research pipeline also includes CT071, an autologous CAR-T therapy that targets GPRC5D. Phase I trials for CT071 are expected to start in 2026 (NCT06333509), and importantly, PCL patients will be eligible to enroll, which is a major step toward inclusivity in research.
The bottom line
While still early, allo-CAR-T therapy may represent a meaningful breakthrough for people facing relapsed or refractory Plasma Cell Leukemia.
These first results, though limited to two patients, signal real progress for a community long left without options.
For those living with PCL, each new study brings more than data; it brings hope.
Sources:
Paul Kleutghen